CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts

British Journal of Cancer

Volumn 100, Issue 6, 2009, Pages 918-922

  Marangoni, E ^a   Lecomte, N ^a,b   Durand, L ^a   De Pinieux, G ^c   Decaudin, D ^a   Chomienne, C ^b   Smadja Joffe, F ^b   Poupon, M F ^a  

^a INSTITUT CURIE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

Breast cancer; CD44; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH INHIBITOR; HERMES ANTIGEN; P 245; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER REGRESSION; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM RECURRENCE, LOCAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 62549090127     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604953     Document Type: Article

References (19)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988
2. Delaunay J, Lecomte N, Bourcier S, Qi J, Gadhoum Z, Durand L, Chomienne C, Robert-Lezenes J, Smadja-Joffe F (2007) Contribution of GM-CSF and IL-8 to the CD44-induced differentiation of acute monoblastic leukemia. Leukemia 22(4): 873-876
3. Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129
4. Fadare O, Tavassoli FA (2008) Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol 5: 149-159
5. Gadhoum Z, Delaunay J, Maquarre E, Durand L, Lancereaux V, Qi J, Robert-Lezenes J, Chromienne C, Smadja-Joffe F (2004) The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. Leuk Lymphoma 45(8): 1501-1510
6. Gotte M, Yip GW (2006) Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66: 10233-10237
7. Hudis CA (2007) Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357: 39-51
8. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174
9. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150
10. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13: 3989-3998
11. Müller-Sieburg CE, Deryugina E, Khaldoyanidi S, O'Rourke A (2000) Tissue- and epitope-specific mechanisms account for the diverse effects of anti-CD44 antibodies on the maintenance of primitive hematopoietic progenitors in vitro. Blood Cells Mol Dis 26(4): 291-302
12. Pagliacci MC, Fumi G, Migliorati G, Grignani F, Riccardi C, Nicoletti I (1993) Cytostatic and cytotoxic effects of tumor necrosis factor alpha on MCF-7 human breast tumor cells are differently inhibited by glucocorticoid hormones. Lymphokine Cytokine Res 12: 439-447
13. Picker LJ, Butcher EC (1992) Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol 10: 561-591
14. Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: 33-45
15. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685
16. Shen WH, Zhou JH, Broussard SR, Freund GG, Dantzer R, Kelley KW (2002) Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor. Cancer Res 62: 4746-4756
17. Subramaniam V, Vincent IR, Gilakjan M, Jothy S (2007) Suppression of human colon cancer tumors in nude mice by siRNA CD44 gene therapy. Exp Mol Pathol 83: 332-340
18. Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, Du Z, Desprez PY, Anver MR, Michalowska AM, Shih J, Parks WT, Wakefield LM (2007) Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res 67: 8643-8652
19. Underhill-Day N, Heath JK (2006) Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel. Cancer Res 66: 10891-10901